Literature DB >> 24122363

Protection of dopaminergic neurons in a mouse model of Parkinson's disease by a physically-modified saline containing charge-stabilized nanobubbles.

Saurabh Khasnavis, Avik Roy, Supurna Ghosh, Richard Watson, Kalipada Pahan.   

Abstract

Neuroinflammation underlies the pathogenesis of various neurodegenerative disorders including Parkinson's disease (PD). Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. RNS60 is a novel therapeutic containing charge-stabilized nanobubbles in saline, generated by subjecting normal saline to Taylor-Couette-Poiseuille flow under elevated oxygen pressure. Recently, we have delineated that RNS60 inhibits the expression of proinflammatory molecules in glial cells via type 1A phosphatidylinositol-3 kinase (PI3K)-mediated upregulation of IκBα. In this study, we demonstrate that RNS60 inhibited the expression of proinflammatory molecules in cultured microglial cells stimulated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridium ion (MPP(+)) and in vivo in the nigra of MPTP-intoxicated mice. While investigating the underlying mechanisms, we found that MPTP intoxication rapidly stimulated the activation of type IB PI3K p110γ in the nigra, while suppressing the activation of type IA PI3K p110α/β. Interestingly, RNS60 treatment suppressed the activation of p110γ PI3K, while inducing the activation of p110α/β PI3K in the nigra of MPTP-intoxicated mice. Accordingly, RNS60 treatment increased the level of IκBα and inhibited the activation of NF-κB in the SNpc of MPTP-intoxicated mice. These findings paralleled dopaminergic neuronal protection, normalized striatal neurotransmitters, and improved motor functions in MPTP-intoxicated mice. These results strongly suggest a promising therapeutic role of this simple modified saline in PD and other neuroinflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24122363     DOI: 10.1007/s11481-013-9503-3

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  32 in total

1.  Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Authors:  Susanta Mondal; Avik Roy; Arundhati Jana; Sankar Ghosh; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-03       Impact factor: 4.147

Review 2.  Signals for the induction of nitric oxide synthase in astrocytes.

Authors:  Ramendra N Saha; Kalipada Pahan
Journal:  Neurochem Int       Date:  2006-06-05       Impact factor: 3.921

3.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 4.  Novel anti-inflammatory therapy for Parkinson's disease.

Authors:  Hui Ming Gao; Bin Liu; Wangqin Zhang; Jau Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2003-08       Impact factor: 14.819

5.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

6.  Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses.

Authors:  Saurav Brahmachari; Arundhati Jana; Kalipada Pahan
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

7.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor.

Authors:  P A Baeuerle; D Baltimore
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

8.  Up-regulation of microglial CD11b expression by nitric oxide.

Authors:  Avik Roy; Yiu K Fung; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2006-03-20       Impact factor: 5.157

9.  Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.

Authors:  S Hunot; F Boissière; B Faucheux; B Brugg; A Mouatt-Prigent; Y Agid; E C Hirsch
Journal:  Neuroscience       Date:  1996-05       Impact factor: 3.590

10.  Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.

Authors:  Susanta Mondal; Jeffrey A Martinson; Supurna Ghosh; Richard Watson; Kalipada Pahan
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  25 in total

1.  Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys.

Authors:  Susanta Mondal; Suresh B Rangasamy; Avik Roy; Sridevi Dasarathy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

2.  Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.

Authors:  Carl G Gottschalk; Malabendu Jana; Avik Roy; Dhruv R Patel; Kalipada Pahan
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.167

3.  Induction of Adaptive Immunity Leads to Nigrostriatal Disease Progression in MPTP Mouse Model of Parkinson's Disease.

Authors:  Goutam Chandra; Avik Roy; Suresh B Rangasamy; Kalipada Pahan
Journal:  J Immunol       Date:  2017-04-26       Impact factor: 5.422

4.  Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey.

Authors:  A Roy; S Mondal; J H Kordower; K Pahan
Journal:  Neuroscience       Date:  2015-03-14       Impact factor: 3.590

5.  Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptorα.

Authors:  Tim Prorok; Malabendu Jana; Dhruv Patel; Kalipada Pahan
Journal:  Neurochem Res       Date:  2019-01-05       Impact factor: 3.996

6.  A pilot trial of RNS60 in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Mohamad J Alshikho; Sarah Luppino; James Chan; Lindsay Pothier; David Schoenfeld; Patricia L Andres; Suma Babu; Nicole R Zürcher; Marco L Loggia; Robert L Barry; Silvia Luotti; Giovanni Nardo; Maria Chiara Trolese; Serena Pantalone; Caterina Bendotti; Valentina Bonetto; Fabiola De Marchi; Bruce Rosen; Jacob Hooker; Merit Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2018-12-26       Impact factor: 3.217

7.  Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Suresh B Rangasamy; Grant T Corbett; Avik Roy; Khushbu K Modi; David A Bennett; Elliott J Mufson; Sankar Ghosh; Kalipada Pahan
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Saurabh Khasnavis; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2014-06-20       Impact factor: 4.147

9.  Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease.

Authors:  Goutam Chandra; Suresh B Rangasamy; Avik Roy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

10.  Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.

Authors:  Suresh B Rangasamy; Sridevi Dasarathi; Priyanka Pahan; Malabendu Jana; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.